On this page

Neomycin and Polymyxin B Sulfates and Dexamethasone

Neomycin Sulfate, Polymyxin B Sulfate, and Dexamethasone · Ointment

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Neomycin and Polymyxin B Sulfates and Dexamethasone
Generic name
Neomycin Sulfate, Polymyxin B Sulfate, and Dexamethasone
Dosage form
Ointment
Route
Ophthalmic
Marketing category
ANDA · ANDA
Labeler
Proficient Rx LP
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
4
NDC product codes
11
Packages
11
Data completeness
83% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Dexamethasone 1 mg/g 197577 View
Neomycin Sulfate 3.5 mg/g 204602 View
Polymyxin B Sulfate 10000 [USP'U]/g 204602 View
Polymyxin B Sulfate 10000 [iU]/g 204602 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Ointment
Route of administration
Ophthalmic
Presentations
22

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Aminoglycoside Antibacterial [EPC] EPC All 66 members
Aminoglycosides [CS] CS All 66 members
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members
Polymyxin-class Antibacterial [EPC] EPC All 55 members
Polymyxins [CS] CS All 55 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
064063
Application type
ANDA · Abbreviated New Drug Application
Approval date
July 25, 1994
Sponsor
BAUSCH AND LOMB INC
Products on application
1
Submissions recorded
23
Products approved under application 064063.
Product Trade name Form Strength Ingredient Status TE Flags
064063-001 NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE OINTMENT DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 064063.
Type No. Action Status Date Review
Supplement 42 Labeling Approved February 7, 2020 Standard
Supplement 41 Labeling Approved February 7, 2020 Standard
Supplement 20 Manufacturing (CMC) Approved August 27, 2002 —
Supplement 19 Manufacturing (CMC) Approved August 27, 2002 —
Supplement 18 Manufacturing (CMC) Approved August 21, 2002 —
Supplement 17 Manufacturing (CMC) Approved February 5, 2002 —
Supplement 16 Manufacturing (CMC) Approved November 27, 2001 —
Supplement 15 Manufacturing (CMC) Approved March 7, 2001 —
Supplement 13 Manufacturing (CMC) Approved August 21, 2000 —
Supplement 14 Manufacturing (CMC) Approved June 27, 2000 —
Supplement 12 Manufacturing (CMC) Approved April 28, 2000 —
Supplement 11 Manufacturing (CMC) Approved June 7, 1999 —
Supplement 8 Manufacturing (CMC) Approved March 30, 1999 —
Supplement 10 Manufacturing (CMC) Approved February 11, 1999 —
Supplement 9 Manufacturing (CMC) Approved November 16, 1998 —
Supplement 6 Manufacturing (CMC) Approved October 22, 1998 —
Supplement 7 Manufacturing (CMC) Approved April 10, 1998 —
Supplement 5 Manufacturing (CMC) Approved July 23, 1997 —
Supplement 4 Labeling Approved July 23, 1997 —
Supplement 3 Manufacturing (CMC) Approved July 23, 1997 —
Supplement 2 Manufacturing (CMC) Approved October 4, 1996 —
Supplement 1 Manufacturing (CMC) Approved January 31, 1996 —
Original application 1 Approved July 25, 1994 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260119). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260119 HUMAN PRESCRIPTION DRUG · 20241231 HUMAN PRESCRIPTION DRUG · 20241031 HUMAN PRESCRIPTION DRUG · 20230501

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE: For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain cases of infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical radiation or thermal burns; or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drugs in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species , Pseudomonas aeruginosa . This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae .

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION: Apply a small amount into the conjunctival sac(s) up to three or four times daily, or may be used adjunctively with Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension at bedtime. How to apply Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment: 1. Tilt your head back. 2. Place a finger on your cheek just under your eye and gently pull down until a "V" pocket is formed between your eyeball and your lower lid. 3. Place a small amount (about 1/2 inch) of Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment in the "V" pocket. Do not let the tip of the tube touch your eye. 4. Look downward before closing your eye. Not more than 8 grams should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS above.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Neomycin and polymyxin B sulfates and dexamethasone ophthalmic ointment is contraindicated in epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and many other viral diseases of the cornea and conjunctiva. Mycobacterial infection of the eye. Fungal diseases of ocular structures. Neomycin and polymyxin B sulfates and dexamethasone ophthalmic ointment is also contraindicated in individuals with known or suspected hypersensitivity to a component of the medication. (Hypersensitivity to the antibiotic component occurs at a higher rate than for other components.)

Warnings and Cautions

openFDA Drug Labeling

Warnings and Precautions NOT FOR INJECTION. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of steroid medication in the treatment of herpes simplex requires great caution; frequent slit lamp microscopy is recommended. Prolonged use may result in glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Prolonged use may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions or parasitic infections of the eye, steroids may mask infection or enhance existing infection. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. If this product is used for 10 days or longer, intraocular pressure (IOP) should be routinely monitored even though it may be difficult in children and uncooperative patients. Steroids should be used with caution in the presence of glaucoma. IOP should be checked frequently. The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. Products containing neomycin sulfate may cause cutaneous sensitization. Sensitivity to topically administered aminoglycosides, such as neomycin, may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If hypersensitivity develops during use of the product, treatment should be discontinued. Cross-hypersensitivity to other aminoglycosides can occur, and the possibility that patients who become sensitized to topical neomycin may also be sensitive to other topical and/or systemic aminoglycosides should be considered. General The initial prescription and renewal of the medication order beyond 8 g of Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment should be made by a physician only after examination of the patient with the aid of magnification, such as a slit lamp biomicroscopy and, where appropriate, fluorescein staining. The possibility of persistent fungal infections of the cornea should be considered after prolonged steroid dosing. Fungal infection should be suspected in patients with persistent corneal ulceration. Information for Patients If inflammation or pain persists longer than 48 hours or becomes aggravated, the patient should be advised to discontinue use of the medication and consult a physician. This product is sterile when packaged. To prevent contamination, care should be taken to avoid touching the tube tip to eyelids or to any other surface. The use of this tube by more than one person may spread infection. Keep tube tightly closed when not in use. Keep out of reach of children. Patients should be advised that their vision may be temporarily blurred following dosing with Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment. Care should be exercised in operating machinery or driving a motor vehicle. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals to evaluate carcinogenic or mutagenic potential have not been conducted with polymyxin B sulfate. Treatment of cultured human lymphocytes in vitro with neomycin increased the frequency of chromosome aberrations at the highest concentration (80 μg/mL) tested. However, the effects of neomycin on carcinogenesis and mutagenesis in humans are unknown. Polymyxin B has been reported to impair the motility of equine sperm, but its effects on male or female fertility are unknown. Pregnancy Dexamethasone has been shown to be teratogenic in mice and rabbits following topical ophthalmic application in multiples of the therapeutic dose. In the mouse, corticosteroids produce fetal resorptions and a specific abnormality, cleft palate. …

WARNINGS NOT FOR INJECTION. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of steroid medication in the treatment of herpes simplex requires great caution; frequent slit lamp microscopy is recommended. Prolonged use may result in glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Prolonged use may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions or parasitic infections of the eye, steroids may mask infection or enhance existing infection. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. If this product is used for 10 days or longer, intraocular pressure (IOP) should be routinely monitored even though it may be difficult in children and uncooperative patients. Steroids should be used with caution in the presence of glaucoma. IOP should be checked frequently. The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. Products containing neomycin sulfate may cause cutaneous sensitization. Sensitivity to topically administered aminoglycosides, such as neomycin, may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If hypersensitivity develops during use of the product, treatment should be discontinued. Cross-hypersensitivity to other aminoglycosides can occur, and the possibility that patients who become sensitized to topical neomycin may also be sensitive to other topical and/or systemic aminoglycosides should be considered.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component, the anti-infective component, or the combination. Exact incidence figures are not available since no denominator of treated patients is available. Reactions occurring most often from the presence of the anti-infective ingredients are allergic sensitizations. The reactions due to the steroid component are: elevation of IOP with possible development of glaucoma, and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing. Secondary Infection: The development of secondary infection has occurred after use of combinations containing steroids and antimicrobials. Fungal infections of the cornea are particularly prone to develop coincidentally with long-term applications of steroid. The possibility of fungal invasion must be considered in any persistent corneal ulceration where steroid treatment has been used. Keratitis, conjunctivitis, corneal ulcers, and conjunctival hyperemia have occasionally been reported following use of steroids. Secondary bacterial ocular infection following suppression of host responses also occurs. Additional adverse reactions identified from post marketing use include ulcerative keratitis, headache, and Stevens-Johnson syndrome. The following additional adverse reactions have been reported with dexamethasone use: Cushing’s syndrome and adrenal suppression may occur after use of dexamethasone in excess of the listed dosing instructions in predisposed patients, including children and patients treated with CYP3A4 inhibitors. To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION: Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment USP is a multiple dose anti-infective steroid combination in a sterile ointment for topical application. The active ingredient dexamethasone, is represented by the following structural formula: C 22 H 29 FO 5 Mol. Wt. 392.47 Chemical Name: Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11β,16α)-. Neomycin Sulfate is the sulfate salt of neomycin B and C which are produced by the growth of Streptomyces fradiae Waksman (Fam. Streptomycetaceae). It has a potency equivalent to not less than 600 micrograms of neomycin base per milligram, calculated on an anhydrous basis. The structural formulae are: Polymyxin B Sulfate is the sulfate salt of polymyxin B 1 and B 2 which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per milligram, calculated on an anhydrous basis. The structural formulae are: Each Gram Contains: ACTIVES: Neomycin Sulfate (equivalent to 3.5 mg Neomycin), Polymyxin B Sulfate, equal to 10,000 polymyxin B units; Dexamethasone 1 mg (0.1%). INACTIVES: White Petrolatum, Lanolin, Mineral Oil. PRESERVATIVES ADDED: Methylparaben 0.05%, Propylparaben 0.01%. Neomycin Sulfate (structural formula) Neomycin Sulfate (structural formula) Polymyxin B Sulfate (structural formula)

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Neomycin and polymyxin B sulfates and dexamethasone ophthalmic ointment, USP is supplied as a sterile ointment in a pre-printed aluminum tube with a natural high density polyethylene (HDPE) cannula and a white HDPE cap. 3.5 g in a aluminum tube NDC 68788-8748-3 Storage: Store between 15°C to 25°C (59°F to 77°F). KEEP OUT OF REACH OF CHILDREN. FOR OPHTHALMIC USE ONLY Distributed by: Bausch & Lomb Americas Inc. Bridgewater, NJ 08807 USA Manufactured by: Bausch & Lomb Incorporated Tampa, FL 33637 USA © 2023 Bausch & Lomb Incorporated or its affiliates Revised: June 2023 Relabeled By: Preferred Pharmaceuticals Inc. DO NOT USE

Adverse event reports

Source: openFDA FAERS
308,304
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: DEXAMETHASONE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Recalls

Source: FDA Enforcement
Drug recall enforcement reports associated with this product.
Classification Reported Firm Reason Status
Class II June 15, 2022 Mckesson Medical-Surgical Inc. Corporate Office cGMP deviations: Temperature abuse Terminated

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
50090-4435-0 50090-4435 A-S Medication Solutions 3.5 g in 1 TUBE (50090-4435-0) July 22, 2019
50090-6181-0 50090-6181 A-S Medication Solutions 1 TUBE in 1 CARTON (50090-6181-0) / 3.5 g in 1 TUBE October 20, 2022
80425-0229-1 80425-0229 Advanced Rx Pharmacy of Tennessee, LLC 1 TUBE in 1 CARTON (80425-0229-1) / 3.5 g in 1 TUBE January 11, 2023
24208-795-35 24208-795 Bausch & Lomb Incorporated 1 TUBE in 1 CARTON (24208-795-35) / 3.5 g in 1 TUBE July 25, 1994
68071-2428-3 68071-2428 NuCare Pharmaceuticals,Inc. 1 TUBE in 1 CARTON (68071-2428-3) / 3.5 g in 1 TUBE June 1, 2021
68071-5281-3 68071-5281 NuCare Pharmaceuticals,Inc. 3.5 g in 1 TUBE (68071-5281-3) June 12, 2020
68788-8748-3 68788-8748 Preferred Pharmaceuticals Inc. 1 TUBE in 1 CARTON (68788-8748-3) / 3.5 g in 1 TUBE October 11, 2024
63187-395-35 63187-395 Proficient Rx LP 1 TUBE in 1 CARTON (63187-395-35) / 3.5 g in 1 TUBE September 1, 2016
63187-669-35 63187-669 Proficient Rx LP 1 TUBE in 1 CARTON (63187-669-35) / 3.5 g in 1 TUBE December 1, 2018
71205-330-35 71205-330 Proficient Rx LP 3.5 g in 1 TUBE (71205-330-35) September 1, 2019
61314-631-36 61314-631 Sandoz Inc 3.5 g in 1 TUBE (61314-631-36) February 21, 1996
50090-4435 50090-4435 A-S Medication Solutions — February 21, 1996
50090-6181 50090-6181 A-S Medication Solutions — July 25, 1994
80425-0229 80425-0229 Advanced Rx Pharmacy of Tennessee, LLC — January 11, 2023
24208-795 24208-795 Bausch & Lomb Incorporated — July 25, 1994
68071-2428 68071-2428 NuCare Pharmaceuticals,Inc. — July 25, 1994
68071-5281 68071-5281 NuCare Pharmaceuticals,Inc. — February 21, 1996
68788-8748 68788-8748 Preferred Pharmaceuticals Inc. — October 11, 2024
63187-395 63187-395 Proficient Rx LP — July 3, 2014
63187-669 63187-669 Proficient Rx LP — July 25, 1994
71205-330 71205-330 Proficient Rx LP — February 21, 1996
61314-631 61314-631 Sandoz Inc — February 21, 1996

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts
Enforcement FDA Recall records

Generated September 25, 2026 · 13 sections on this page.